Dengue vaccine: The current status

Medical Journal Armed Forces India

Volumn 64, Issue 2, 2008, Pages 161-164

  Mustafa, M S ^a   Agrawal, V K ^b  

^a DADH   (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Candidate vaccines; Clinical trials; Dengue fever

Indexed keywords

CHIMERIC ANTIBODY; DENGUE VACCINE; DNA VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ARTICLE; BACULOVIRUS; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG FORMULATION; DRUG RESEARCH; FLAVIVIRUS; FUNDING; HUMAN; MOLECULAR CLONING; NONHUMAN; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL GENETICS;

EID: 44949145366     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0377-1237(08)80065-2     Document Type: Article

References (19)

1. Gubler DJ. Dengue and dengue haemorrhagic fever. Clin Microbiol Review 1998; 11: 480-96.
2. Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res 2005; 5: 639-52.
3. Craig S, Thu HL, Lowry K. Diverse dengue Type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol 2003; 77: 4463-7.
4. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005; 83: 308-14.
5. Lancotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol 1992; 30: 545-51.
6. Kanesa-thasan N, Sun W, Kim-Ahn G. Safety and immunogenicity of attenuated dengue virus vaccines in human volunteers. Vaccine 2001; 19: 3179-88.
7. Sabchareon A, Lang J, Chanthavanich P. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66: 264-72.
8. Blaney E, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79: 5516-28.
9. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360: 1243-5.
10. Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 1996; 70: 4162-6.
11. Butrapet S, Kinney RM, Huang CY. Determining genetic stabilities of chimaeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative Taq MAMA. J Virol 2006; 13: 1-9.
12. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30-nucleotide deletion in its 3′- untranslated region. Am J Trop Med Hyg 2001; 65: 405-13.
13. Guirakhoo F, et al. Recombinant chimaeric yellow fever-dengue, Type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74: 5477-85.
14. Guirakhoo F. Viraemia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimaeric vaccine: Genetic reconstructions, dose adjustment and antibody responses against wild-type dengue virus isolates. J Virol 2002; 298: 146-59.
15. Guirakhoo F, Bolin RA, Roehrig JT. The Murray valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of the E glycoprotein. J Virol 1992; 191: 911-31.
16. Ertl HCJ, Xiang Z. Novel vaccine approaches. J Immunol 1996, 56:3579-82.
17. Men R. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue Type 2 virus challenge. Vaccine 2000; 18: 3113-22.
18. Jacqueline LD. The challenge of dengue vaccine development and introduction. Trop Med and International Health 2004; 9: 1-3.
19. Kinney RM, Huang, CY. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 2001; 44: 176-97.